APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drugs for PrEP

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drugs for PrEP Market Analysis and Forecast 2026-2032

Report ID 173986460229 December 2025197 pages

Choose your research edition.

Industry ResearchDrugs for PrEP Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for PrEP Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Drugs for PrEP Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for PrEP Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for PrEP Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Drugs for PrEP market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Drugs for PrEP is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drugs for PrEP is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drugs for PrEP is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drugs for PrEP is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Drugs for PrEP include Chia Tai Tianqing Pharmaceutical, Qilu Pharmaceutical, North China Pharmaceutical, Chengdu Brilliant Pharmaceutical, Anhui Baker Biopharmaceutical, Zydus, ViiV Healthcare, Teva and Mylan, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Drugs for PrEP, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drugs for PrEP, also provides the sales of main regions and countries. Of the upcoming market potential for Drugs for PrEP, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for PrEP sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drugs for PrEP market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Drugs for PrEP sales, projected growth trends, production technology, application and end-user industry.

Drugs for PrEP Segment by Company

Chia Tai Tianqing Pharmaceutical

Qilu Pharmaceutical

North China Pharmaceutical

Chengdu Brilliant Pharmaceutical

Anhui Baker Biopharmaceutical

Zydus

ViiV Healthcare

Teva

Mylan

Gilead Sciences

Aurobindo Pharma

Amneal Pharmaceuticals

Drugs for PrEP Segment by Type

Oral Drugs

Injections

Drugs for PrEP Segment by Application

Hospital and Clinic

Pharmacy

Other

Drugs for PrEP Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for PrEP market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for PrEP and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for PrEP.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Drugs for PrEP in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Drugs for PrEP manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for PrEP sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs for PrEP Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Drugs Major Manufacturers Table 3. Injections Major Manufacturers Table 4. Global Drugs for PrEP Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital and Clinic Major Manufacturers Table 6. Pharmacy Major Manufacturers Table 7. Other Major Manufacturers Table 8. Drugs for PrEP Industry Trends Table 9. Drugs for PrEP Industry Drivers Table 10. Drugs for PrEP Industry Opportunities and Challenges Table 11. Drugs for PrEP Industry Restraints Table 12. Global Drugs for PrEP Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Drugs for PrEP Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Drugs for PrEP Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Drugs for PrEP Revenue Market Share by Region (2021-2026) Table 16. Global Drugs for PrEP Revenue Market Share by Region (2027-2032) Table 17. Global Drugs for PrEP Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Drugs for PrEP Sales by Region (2021-2026) & (K Units) Table 19. Global Drugs for PrEP Sales by Region (2027-2032) & (K Units) Table 20. Global Drugs for PrEP Sales Market Share by Region (2021-2026) Table 21. Global Drugs for PrEP Sales Market Share by Region (2027-2032) Table 22. Global Drugs for PrEP Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Drugs for PrEP Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Drugs for PrEP Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Drugs for PrEP Sales Market Share by Manufacturers (2021-2026) Table 26. Global Drugs for PrEP Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Drugs for PrEP Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Drugs for PrEP Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Drugs for PrEP Manufacturers, Product Type & Application Table 30. Global Drugs for PrEP Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Drugs for PrEP by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Drugs for PrEP Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Drugs for PrEP Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Drugs for PrEP Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Drugs for PrEP Revenue Market Share by Type (2021-2026) Table 37. Global Drugs for PrEP Revenue Market Share by Type (2027-2032) Table 38. Global Drugs for PrEP Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Drugs for PrEP Sales by Type (2021-2026) & (K Units) Table 40. Global Drugs for PrEP Sales by Type (2027-2032) & (K Units) Table 41. Global Drugs for PrEP Sales Market Share by Type (2021-2026) Table 42. Global Drugs for PrEP Sales Market Share by Type (2027-2032) Table 43. Global Drugs for PrEP Price by Type (2021-2026) & (US$/Unit) Table 44. Global Drugs for PrEP Price by Type (2027-2032) & (US$/Unit) Table 45. Global Drugs for PrEP Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Drugs for PrEP Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Drugs for PrEP Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Drugs for PrEP Revenue Market Share by Application (2021-2026) Table 49. Global Drugs for PrEP Revenue Market Share by Application (2027-2032) Table 50. Global Drugs for PrEP Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Drugs for PrEP Sales by Application (2021-2026) & (K Units) Table 52. Global Drugs for PrEP Sales by Application (2027-2032) & (K Units) Table 53. Global Drugs for PrEP Sales Market Share by Application (2021-2026) Table 54. Global Drugs for PrEP Sales Market Share by Application (2027-2032) Table 55. Global Drugs for PrEP Price by Application (2021-2026) & (US$/Unit) Table 56. Global Drugs for PrEP Price by Application (2027-2032) & (US$/Unit) Table 57. Chia Tai Tianqing Pharmaceutical Company Information Table 58. Chia Tai Tianqing Pharmaceutical Business Overview Table 59. Chia Tai Tianqing Pharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Chia Tai Tianqing Pharmaceutical Drugs for PrEP Product Portfolio Table 61. Chia Tai Tianqing Pharmaceutical Recent Development Table 62. Qilu Pharmaceutical Company Information Table 63. Qilu Pharmaceutical Business Overview Table 64. Qilu Pharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Qilu Pharmaceutical Drugs for PrEP Product Portfolio Table 66. Qilu Pharmaceutical Recent Development Table 67. North China Pharmaceutical Company Information Table 68. North China Pharmaceutical Business Overview Table 69. North China Pharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. North China Pharmaceutical Drugs for PrEP Product Portfolio Table 71. North China Pharmaceutical Recent Development Table 72. Chengdu Brilliant Pharmaceutical Company Information Table 73. Chengdu Brilliant Pharmaceutical Business Overview Table 74. Chengdu Brilliant Pharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Chengdu Brilliant Pharmaceutical Drugs for PrEP Product Portfolio Table 76. Chengdu Brilliant Pharmaceutical Recent Development Table 77. Anhui Baker Biopharmaceutical Company Information Table 78. Anhui Baker Biopharmaceutical Business Overview Table 79. Anhui Baker Biopharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Anhui Baker Biopharmaceutical Drugs for PrEP Product Portfolio Table 81. Anhui Baker Biopharmaceutical Recent Development Table 82. Zydus Company Information Table 83. Zydus Business Overview Table 84. Zydus Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Zydus Drugs for PrEP Product Portfolio Table 86. Zydus Recent Development Table 87. ViiV Healthcare Company Information Table 88. ViiV Healthcare Business Overview Table 89. ViiV Healthcare Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. ViiV Healthcare Drugs for PrEP Product Portfolio Table 91. ViiV Healthcare Recent Development Table 92. Teva Company Information Table 93. Teva Business Overview Table 94. Teva Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Teva Drugs for PrEP Product Portfolio Table 96. Teva Recent Development Table 97. Mylan Company Information Table 98. Mylan Business Overview Table 99. Mylan Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Mylan Drugs for PrEP Product Portfolio Table 101. Mylan Recent Development Table 102. Gilead Sciences Company Information Table 103. Gilead Sciences Business Overview Table 104. Gilead Sciences Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Gilead Sciences Drugs for PrEP Product Portfolio Table 106. Gilead Sciences Recent Development Table 107. Aurobindo Pharma Company Information Table 108. Aurobindo Pharma Business Overview Table 109. Aurobindo Pharma Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Aurobindo Pharma Drugs for PrEP Product Portfolio Table 111. Aurobindo Pharma Recent Development Table 112. Amneal Pharmaceuticals Company Information Table 113. Amneal Pharmaceuticals Business Overview Table 114. Amneal Pharmaceuticals Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Amneal Pharmaceuticals Drugs for PrEP Product Portfolio Table 116. Amneal Pharmaceuticals Recent Development Table 117. North America Drugs for PrEP Revenue by Type (2021-2026) & (US$ Million) Table 118. North America Drugs for PrEP Revenue by Type (2027-2032) & (US$ Million) Table 119. North America Drugs for PrEP Sales by Type (2021-2026) & (K Units) Table 120. North America Drugs for PrEP Sales by Type (2027-2032) & (K Units) Table 121. North America Drugs for PrEP Sales Price by Type (2021-2026) & (US$/Unit) Table 122. North America Drugs for PrEP Sales Price by Type (2027-2032) & (US$/Unit) Table 123. North America Drugs for PrEP Revenue by Application (2021-2026) & (US$ Million) Table 124. North America Drugs for PrEP Revenue by Application (2027-2032) & (US$ Million) Table 125. North America Drugs for PrEP Sales by Application (2021-2026) & (K Units) Table 126. North America Drugs for PrEP Sales by Application (2027-2032) & (K Units) Table 127. North America Drugs for PrEP Sales Price by Application (2021-2026) & (US$/Unit) Table 128. North America Drugs for PrEP Sales Price by Application (2027-2032) & (US$/Unit) Table 129. North America Drugs for PrEP Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 130. North America Drugs for PrEP Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 131. North America Drugs for PrEP Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 132. North America Drugs for PrEP Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 133. North America Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 134. North America Drugs for PrEP Sales by Country (2027-2032) & (K Units) Table 135. North America Drugs for PrEP Sales Price by Country (2021-2026) & (US$/Unit) Table 136. North America Drugs for PrEP Sales Price by Country (2027-2032) & (US$/Unit) Table 137. United States Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 138. Canada Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 139. Mexico Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 140. Europe Drugs for PrEP Revenue by Type (2021-2026) & (US$ Million) Table 141. Europe Drugs for PrEP Revenue by Type (2027-2032) & (US$ Million) Table 142. Europe Drugs for PrEP Sales by Type (2021-2026) & (K Units) Table 143. Europe Drugs for PrEP Sales by Type (2027-2032) & (K Units) Table 144. Europe Drugs for PrEP Sales Price by Type (2021-2026) & (US$/Unit) Table 145. Europe Drugs for PrEP Sales Price by Type (2027-2032) & (US$/Unit) Table 146. Europe Drugs for PrEP Revenue by Application (2021-2026) & (US$ Million) Table 147. Europe Drugs for PrEP Revenue by Application (2027-2032) & (US$ Million) Table 148. Europe Drugs for PrEP Sales by Application (2021-2026) & (K Units) Table 149. Europe Drugs for PrEP Sales by Application (2027-2032) & (K Units) Table 150. Europe Drugs for PrEP Sales Price by Application (2021-2026) & (US$/Unit) Table 151. Europe Drugs for PrEP Sales Price by Application (2027-2032) & (US$/Unit) Table 152. Europe Drugs for PrEP Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 153. Europe Drugs for PrEP Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 154. Europe Drugs for PrEP Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 155. Europe Drugs for PrEP Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 156. Europe Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 157. Europe Drugs for PrEP Sales by Country (2027-2032) & (K Units) Table 158. Europe Drugs for PrEP Sales Price by Country (2021-2026) & (US$/Unit) Table 159. Europe Drugs for PrEP Sales Price by Country (2027-2032) & (US$/Unit) Table 160. Germany Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 161. France Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 162. U.K. Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 163. Italy Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 164. Russia Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 165. Spain Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 166. Netherlands Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 167. Switzerland Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 168. Sweden Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 169. Poland Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 170. China Drugs for PrEP Revenue by Type (2021-2026) & (US$ Million) Table 171. China Drugs for PrEP Revenue by Type (2027-2032) & (US$ Million) Table 172. China Drugs for PrEP Sales by Type (2021-2026) & (K Units) Table 173. China Drugs for PrEP Sales by Type (2027-2032) & (K Units) Table 174. China Drugs for PrEP Sales Price by Type (2021-2026) & (US$/Unit) Table 175. China Drugs for PrEP Sales Price by Type (2027-2032) & (US$/Unit) Table 176. China Drugs for PrEP Revenue by Application (2021-2026) & (US$ Million) Table 177. China Drugs for PrEP Revenue by Application (2027-2032) & (US$ Million) Table 178. China Drugs for PrEP Sales by Application (2021-2026) & (K Units) Table 179. China Drugs for PrEP Sales by Application (2027-2032) & (K Units) Table 180. China Drugs for PrEP Sales Price by Application (2021-2026) & (US$/Unit) Table 181. China Drugs for PrEP Sales Price by Application (2027-2032) & (US$/Unit) Table 182. Asia Drugs for PrEP Revenue by Type (2021-2026) & (US$ Million) Table 183. Asia Drugs for PrEP Revenue by Type (2027-2032) & (US$ Million) Table 184. Asia Drugs for PrEP Sales by Type (2021-2026) & (K Units) Table 185. Asia Drugs for PrEP Sales by Type (2027-2032) & (K Units) Table 186. Asia Drugs for PrEP Sales Price by Type (2021-2026) & (US$/Unit) Table 187. Asia Drugs for PrEP Sales Price by Type (2027-2032) & (US$/Unit) Table 188. Asia Drugs for PrEP Revenue by Application (2021-2026) & (US$ Million) Table 189. Asia Drugs for PrEP Revenue by Application (2027-2032) & (US$ Million) Table 190. Asia Drugs for PrEP Sales by Application (2021-2026) & (K Units) Table 191. Asia Drugs for PrEP Sales by Application (2027-2032) & (K Units) Table 192. Asia Drugs for PrEP Sales Price by Application (2021-2026) & (US$/Unit) Table 193. Asia Drugs for PrEP Sales Price by Application (2027-2032) & (US$/Unit) Table 194. Asia Drugs for PrEP Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 195. Asia Drugs for PrEP Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 196. Asia Drugs for PrEP Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 197. Asia Drugs for PrEP Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 198. Asia Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 199. Asia Drugs for PrEP Sales by Country (2027-2032) & (K Units) Table 200. Asia Drugs for PrEP Sales Price by Country (2021-2026) & (US$/Unit) Table 201. Asia Drugs for PrEP Sales Price by Country (2027-2032) & (US$/Unit) Table 202. Japan Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 203. South Korea Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 204. India Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 205. Australia Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 206. Taiwan Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 207. Southeast Asia Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 208. SAMEA Drugs for PrEP Revenue by Type (2021-2026) & (US$ Million) Table 209. SAMEA Drugs for PrEP Revenue by Type (2027-2032) & (US$ Million) Table 210. SAMEA Drugs for PrEP Sales by Type (2021-2026) & (K Units) Table 211. SAMEA Drugs for PrEP Sales by Type (2027-2032) & (K Units) Table 212. SAMEA Drugs for PrEP Sales Price by Type (2021-2026) & (US$/Unit) Table 213. SAMEA Drugs for PrEP Sales Price by Type (2027-2032) & (US$/Unit) Table 214. SAMEA Drugs for PrEP Revenue by Application (2021-2026) & (US$ Million) Table 215. SAMEA Drugs for PrEP Revenue by Application (2027-2032) & (US$ Million) Table 216. SAMEA Drugs for PrEP Sales by Application (2021-2026) & (K Units) Table 217. SAMEA Drugs for PrEP Sales by Application (2027-2032) & (K Units) Table 218. SAMEA Drugs for PrEP Sales Price by Application (2021-2026) & (US$/Unit) Table 219. SAMEA Drugs for PrEP Sales Price by Application (2027-2032) & (US$/Unit) Table 220. SAMEA Drugs for PrEP Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 221. SAMEA Drugs for PrEP Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 222. SAMEA Drugs for PrEP Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 223. SAMEA Drugs for PrEP Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 224. SAMEA Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 225. SAMEA Drugs for PrEP Sales by Country (2027-2032) & (K Units) Table 226. SAMEA Drugs for PrEP Sales Price by Country (2021-2026) & (US$/Unit) Table 227. SAMEA Drugs for PrEP Sales Price by Country (2027-2032) & (US$/Unit) Table 228. Brazil Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 229. Argentina Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 230. Chile Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 231. Colombia Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 232. Peru Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 233. Saudi Arabia Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 234. Israel Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 235. UAE Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 236. Turkey Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 237. Iran Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 238. Egypt Drugs for PrEP Revenue (2021-2032) & (US$ Million) Table 239. Key Raw Materials Table 240. Raw Materials Key Suppliers Table 241. Drugs for PrEP Distributors List Table 242. Drugs for PrEP Customers List Table 243. Research Programs/Design for This Report Table 244. Authors List of This Report Table 245. Secondary Sources Table 246. Primary Sources List of Figures Figure 1. Drugs for PrEP Image Figure 2. Global Drugs for PrEP Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for PrEP Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Drugs Image Figure 5. Injections Image Figure 6. Global Drugs for PrEP Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Drugs for PrEP Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital and Clinic Image Figure 9. Pharmacy Image Figure 10. Other Image Figure 11. Global Drugs for PrEP Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Drugs for PrEP Revenue (2021-2032) & (US$ Million) Figure 13. Global Drugs for PrEP Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Drugs for PrEP Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Drugs for PrEP Revenue Market Share by Region (2021-2032) Figure 16. Global Drugs for PrEP Sales (2021-2032) & (K Units) Figure 17. Global Drugs for PrEP Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Drugs for PrEP Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Drugs for PrEP Sales YoY (2021-2032) & (K Units) Figure 20. Europe Drugs for PrEP Sales YoY (2021-2032) & (K Units) Figure 21. China Drugs for PrEP Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Drugs for PrEP Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Drugs for PrEP Sales YoY (2021-2032) & (K Units) Figure 24. Global Drugs for PrEP Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Drugs for PrEP Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Drugs for PrEP Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Drugs for PrEP Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Drugs for PrEP Revenue Market Share by Type (2021-2032) Figure 30. Global Drugs for PrEP Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Drugs for PrEP Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Drugs for PrEP Sales Market Share by Type (2021-2032) Figure 33. Global Drugs for PrEP Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Drugs for PrEP Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Drugs for PrEP Revenue Market Share by Application (2021-2032) Figure 36. Global Drugs for PrEP Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Drugs for PrEP Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Drugs for PrEP Sales Market Share by Application (2021-2032) Figure 39. North America Drugs for PrEP Revenue Share by Type (2021-2032) Figure 40. North America Drugs for PrEP Sales Share by Type (2021-2032) Figure 41. North America Drugs for PrEP Revenue Share by Application (2021-2032) Figure 42. North America Drugs for PrEP Sales Share by Application (2021-2032) Figure 43. North America Drugs for PrEP Revenue Share by Country (2021-2032) Figure 44. North America Drugs for PrEP Sales Share by Country (2021-2032) Figure 45. Europe Drugs for PrEP Revenue Share by Type (2021-2032) Figure 46. Europe Drugs for PrEP Sales Share by Type (2021-2032) Figure 47. Europe Drugs for PrEP Revenue Share by Application (2021-2032) Figure 48. Europe Drugs for PrEP Sales Share by Application (2021-2032) Figure 49. Europe Drugs for PrEP Revenue Share by Country (2021-2032) Figure 50. Europe Drugs for PrEP Sales Share by Country (2021-2032) Figure 51. China Drugs for PrEP Revenue Share by Type (2021-2032) Figure 52. China Drugs for PrEP Sales Share by Type (2021-2032) Figure 53. China Drugs for PrEP Revenue Share by Application (2021-2032) Figure 54. China Drugs for PrEP Sales Share by Application (2021-2032) Figure 55. Asia Drugs for PrEP Revenue Share by Type (2021-2032) Figure 56. Asia Drugs for PrEP Sales Share by Type (2021-2032) Figure 57. Asia Drugs for PrEP Revenue Share by Application (2021-2032) Figure 58. Asia Drugs for PrEP Sales Share by Application (2021-2032) Figure 59. Asia Drugs for PrEP Revenue Share by Country (2021-2032) Figure 60. Asia Drugs for PrEP Sales Share by Country (2021-2032) Figure 61. SAMEA Drugs for PrEP Revenue Share by Type (2021-2032) Figure 62. SAMEA Drugs for PrEP Sales Share by Type (2021-2032) Figure 63. SAMEA Drugs for PrEP Revenue Share by Application (2021-2032) Figure 64. SAMEA Drugs for PrEP Sales Share by Application (2021-2032) Figure 65. SAMEA Drugs for PrEP Revenue Share by Country (2021-2032) Figure 66. SAMEA Drugs for PrEP Sales Share by Country (2021-2032) Figure 67. Drugs for PrEP Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Drugs for PrEP Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Drugs
  • Injections
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Qilu Pharmaceutical
  • North China Pharmaceutical
  • Chengdu Brilliant Pharmaceutical
  • Anhui Baker Biopharmaceutical
  • Zydus
  • ViiV Healthcare
  • Teva
  • Mylan
  • Gilead Sciences
  • Aurobindo Pharma
  • Amneal Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drugs for PrEP Market by Type
  3. 1.2.1 Global Drugs for PrEP Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral Drugs
  5. 1.2.3 Injections
  6. 1.3 Drugs for PrEP Market by Application
  7. 1.3.1 Global Drugs for PrEP Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital and Clinic
  9. 1.3.3 Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Drugs for PrEP Market Dynamics
  1. 2.1 Drugs for PrEP Industry Trends
  2. 2.2 Drugs for PrEP Industry Drivers
  3. 2.3 Drugs for PrEP Industry Opportunities and Challenges
  4. 2.4 Drugs for PrEP Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Drugs for PrEP Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Drugs for PrEP Revenue by Region
  3. 3.2.1 Global Drugs for PrEP Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drugs for PrEP Revenue by Region (2021-2026)
  5. 3.2.3 Global Drugs for PrEP Revenue by Region (2027-2032)
  6. 3.2.4 Global Drugs for PrEP Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Drugs for PrEP Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Drugs for PrEP Sales by Region
  9. 3.4.1 Global Drugs for PrEP Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Drugs for PrEP Sales by Region (2021-2026)
  11. 3.4.3 Global Drugs for PrEP Sales by Region (2027-2032)
  12. 3.4.4 Global Drugs for PrEP Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Drugs for PrEP Revenue by Manufacturers
  2. 4.1.1 Global Drugs for PrEP Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Drugs for PrEP Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Drugs for PrEP Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drugs for PrEP Sales by Manufacturers
  6. 4.2.1 Global Drugs for PrEP Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Drugs for PrEP Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Drugs for PrEP Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Drugs for PrEP Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Drugs for PrEP Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Drugs for PrEP Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Drugs for PrEP Manufacturers, Product Type & Application
  13. 4.7 Global Drugs for PrEP Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Drugs for PrEP Market CR5 and HHI
  16. 4.8.2 2025 Drugs for PrEP Tier 1, Tier 2, and Tier 3
5 Drugs for PrEP Market by Type
  1. 5.1 Global Drugs for PrEP Revenue by Type
  2. 5.1.1 Global Drugs for PrEP Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Drugs for PrEP Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Drugs for PrEP Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Drugs for PrEP Sales by Type
  6. 5.2.1 Global Drugs for PrEP Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for PrEP Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Drugs for PrEP Sales Market Share by Type (2021-2032)
  9. 5.3 Global Drugs for PrEP Price by Type
6 Drugs for PrEP Market by Application
  1. 6.1 Global Drugs for PrEP Revenue by Application
  2. 6.1.1 Global Drugs for PrEP Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Drugs for PrEP Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Drugs for PrEP Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Drugs for PrEP Sales by Application
  6. 6.2.1 Global Drugs for PrEP Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Drugs for PrEP Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Drugs for PrEP Sales Market Share by Application (2021-2032)
  9. 6.3 Global Drugs for PrEP Price by Application
7 Company Profiles
  1. 7.1 Chia Tai Tianqing Pharmaceutical
  2. 7.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 7.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 7.1.3 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Product Portfolio
  6. 7.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 7.2 Qilu Pharmaceutical
  8. 7.2.1 Qilu Pharmaceutical Company Information
  9. 7.2.2 Qilu Pharmaceutical Business Overview
  10. 7.2.3 Qilu Pharmaceutical Drugs for PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Qilu Pharmaceutical Drugs for PrEP Product Portfolio
  12. 7.2.5 Qilu Pharmaceutical Recent Developments
  13. 7.3 North China Pharmaceutical
  14. 7.3.1 North China Pharmaceutical Company Information
  15. 7.3.2 North China Pharmaceutical Business Overview
  16. 7.3.3 North China Pharmaceutical Drugs for PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 North China Pharmaceutical Drugs for PrEP Product Portfolio
  18. 7.3.5 North China Pharmaceutical Recent Developments
  19. 7.4 Chengdu Brilliant Pharmaceutical
  20. 7.4.1 Chengdu Brilliant Pharmaceutical Company Information
  21. 7.4.2 Chengdu Brilliant Pharmaceutical Business Overview
  22. 7.4.3 Chengdu Brilliant Pharmaceutical Drugs for PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Chengdu Brilliant Pharmaceutical Drugs for PrEP Product Portfolio
  24. 7.4.5 Chengdu Brilliant Pharmaceutical Recent Developments
  25. 7.5 Anhui Baker Biopharmaceutical
  26. 7.5.1 Anhui Baker Biopharmaceutical Company Information
  27. 7.5.2 Anhui Baker Biopharmaceutical Business Overview
  28. 7.5.3 Anhui Baker Biopharmaceutical Drugs for PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Anhui Baker Biopharmaceutical Drugs for PrEP Product Portfolio
  30. 7.5.5 Anhui Baker Biopharmaceutical Recent Developments
  31. 7.6 Zydus
  32. 7.6.1 Zydus Company Information
  33. 7.6.2 Zydus Business Overview
  34. 7.6.3 Zydus Drugs for PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Zydus Drugs for PrEP Product Portfolio
  36. 7.6.5 Zydus Recent Developments
  37. 7.7 ViiV Healthcare
  38. 7.7.1 ViiV Healthcare Company Information
  39. 7.7.2 ViiV Healthcare Business Overview
  40. 7.7.3 ViiV Healthcare Drugs for PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 ViiV Healthcare Drugs for PrEP Product Portfolio
  42. 7.7.5 ViiV Healthcare Recent Developments
  43. 7.8 Teva
  44. 7.8.1 Teva Company Information
  45. 7.8.2 Teva Business Overview
  46. 7.8.3 Teva Drugs for PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Teva Drugs for PrEP Product Portfolio
  48. 7.8.5 Teva Recent Developments
  49. 7.9 Mylan
  50. 7.9.1 Mylan Company Information
  51. 7.9.2 Mylan Business Overview
  52. 7.9.3 Mylan Drugs for PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Mylan Drugs for PrEP Product Portfolio
  54. 7.9.5 Mylan Recent Developments
  55. 7.10 Gilead Sciences
  56. 7.10.1 Gilead Sciences Company Information
  57. 7.10.2 Gilead Sciences Business Overview
  58. 7.10.3 Gilead Sciences Drugs for PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Gilead Sciences Drugs for PrEP Product Portfolio
  60. 7.10.5 Gilead Sciences Recent Developments
  61. 7.11 Aurobindo Pharma
  62. 7.11.1 Aurobindo Pharma Company Information
  63. 7.11.2 Aurobindo Pharma Business Overview
  64. 7.11.3 Aurobindo Pharma Drugs for PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Aurobindo Pharma Drugs for PrEP Product Portfolio
  66. 7.11.5 Aurobindo Pharma Recent Developments
  67. 7.12 Amneal Pharmaceuticals
  68. 7.12.1 Amneal Pharmaceuticals Company Information
  69. 7.12.2 Amneal Pharmaceuticals Business Overview
  70. 7.12.3 Amneal Pharmaceuticals Drugs for PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Amneal Pharmaceuticals Drugs for PrEP Product Portfolio
  72. 7.12.5 Amneal Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Drugs for PrEP Market Size by Type
  2. 8.1.1 North America Drugs for PrEP Revenue by Type (2021-2032)
  3. 8.1.2 North America Drugs for PrEP Sales by Type (2021-2032)
  4. 8.1.3 North America Drugs for PrEP Price by Type (2021-2032)
  5. 8.2 North America Drugs for PrEP Market Size by Application
  6. 8.2.1 North America Drugs for PrEP Revenue by Application (2021-2032)
  7. 8.2.2 North America Drugs for PrEP Sales by Application (2021-2032)
  8. 8.2.3 North America Drugs for PrEP Price by Application (2021-2032)
  9. 8.3 North America Drugs for PrEP Market Size by Country
  10. 8.3.1 North America Drugs for PrEP Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Drugs for PrEP Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Drugs for PrEP Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Drugs for PrEP Market Size by Type
  2. 9.1.1 Europe Drugs for PrEP Revenue by Type (2021-2032)
  3. 9.1.2 Europe Drugs for PrEP Sales by Type (2021-2032)
  4. 9.1.3 Europe Drugs for PrEP Price by Type (2021-2032)
  5. 9.2 Europe Drugs for PrEP Market Size by Application
  6. 9.2.1 Europe Drugs for PrEP Revenue by Application (2021-2032)
  7. 9.2.2 Europe Drugs for PrEP Sales by Application (2021-2032)
  8. 9.2.3 Europe Drugs for PrEP Price by Application (2021-2032)
  9. 9.3 Europe Drugs for PrEP Market Size by Country
  10. 9.3.1 Europe Drugs for PrEP Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Drugs for PrEP Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Drugs for PrEP Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Drugs for PrEP Market Size by Type
  2. 10.1.1 China Drugs for PrEP Revenue by Type (2021-2032)
  3. 10.1.2 China Drugs for PrEP Sales by Type (2021-2032)
  4. 10.1.3 China Drugs for PrEP Price by Type (2021-2032)
  5. 10.2 China Drugs for PrEP Market Size by Application
  6. 10.2.1 China Drugs for PrEP Revenue by Application (2021-2032)
  7. 10.2.2 China Drugs for PrEP Sales by Application (2021-2032)
  8. 10.2.3 China Drugs for PrEP Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drugs for PrEP Market Size by Type
  2. 11.1.1 Asia Drugs for PrEP Revenue by Type (2021-2032)
  3. 11.1.2 Asia Drugs for PrEP Sales by Type (2021-2032)
  4. 11.1.3 Asia Drugs for PrEP Price by Type (2021-2032)
  5. 11.2 Asia Drugs for PrEP Market Size by Application
  6. 11.2.1 Asia Drugs for PrEP Revenue by Application (2021-2032)
  7. 11.2.2 Asia Drugs for PrEP Sales by Application (2021-2032)
  8. 11.2.3 Asia Drugs for PrEP Price by Application (2021-2032)
  9. 11.3 Asia Drugs for PrEP Market Size by Country
  10. 11.3.1 Asia Drugs for PrEP Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Drugs for PrEP Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Drugs for PrEP Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drugs for PrEP Market Size by Type
  2. 12.1.1 SAMEA Drugs for PrEP Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Drugs for PrEP Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Drugs for PrEP Price by Type (2021-2032)
  5. 12.2 SAMEA Drugs for PrEP Market Size by Application
  6. 12.2.1 SAMEA Drugs for PrEP Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Drugs for PrEP Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Drugs for PrEP Price by Application (2021-2032)
  9. 12.3 SAMEA Drugs for PrEP Market Size by Country
  10. 12.3.1 SAMEA Drugs for PrEP Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Drugs for PrEP Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Drugs for PrEP Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Drugs for PrEP Value Chain Analysis
  2. 13.1.1 Drugs for PrEP Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Drugs for PrEP Production Mode & Process
  6. 13.2 Drugs for PrEP Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Drugs for PrEP Distributors
  9. 13.2.3 Drugs for PrEP Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst